Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Piper confident in Opko's somatrogon approval despite BLA review delay » 17:27
09/24/21
09/24
17:27
09/24/21
17:27
OPK

Opko Health

$3.76 /

-0.125 (-3.22%)

, PFE

Pfizer

$43.94 /

-0.25 (-0.57%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $5 price target on Opko Health (OPK) after the FDA extended the BLA review period for once-weekly somatrogon for pediatric growth hormone deficiency to January 2022. Tenthoff said that, despite the delay, he remains confident in approval based on positive Phase III data. The anlayst noted that the somatrogon MAA was validated in Europe and Pfizer (PFE) submitted the NDA in Japan.

ShowHide Related Items >><<
PFE Pfizer
$43.94 /

-0.25 (-0.57%)

OPK Opko Health
$3.76 /

-0.125 (-3.22%)

OPK Opko Health
$3.76 /

-0.125 (-3.22%)

07/30/21 Barrington
Opko Health price target lowered to $6 from $8 at Barrington
06/21/21 Ladenburg
Ladenburg starts 'diverse' Opko Health at Buy with $7 price target
06/21/21 Ladenburg
Opko Health initiated with a Buy at Ladenburg
02/19/21 Barrington
Opko Health price target raised to $8 from $7 at Barrington
PFE Pfizer
$43.94 /

-0.25 (-0.57%)

09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
PFE Pfizer
$43.94 /

-0.25 (-0.57%)

OPK Opko Health
$3.76 /

-0.125 (-3.22%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

OPK Opko Health
$3.76 /

-0.125 (-3.22%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

Hot Stocks
Pfizer, OPKO announce FDA extension of review period for somatrogon BLA » 16:26
09/24/21
09/24
16:26
09/24/21
16:26
PFE

Pfizer

$43.94 /

-0.25 (-0.57%)

, OPK

Opko Health

$3.76 /

-0.125 (-3.22%)

Pfizer (PFE) and OPKO…

Pfizer (PFE) and OPKO Health (OPK) announced that the FDA has extended the review period for the Biologics License Application, BLA, for somatrogon, a once-weekly long-acting recombinant human growth hormone, for the treatment of growth hormone deficiency in pediatric patients. The PDUFA goal date has been extended by three months to January 2022, as a result of Pfizer's submission of additional data to the original BLA. In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD. Under the agreement, OPKO is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product for GHD.

ShowHide Related Items >><<
PFE Pfizer
$43.94 /

-0.25 (-0.57%)

OPK Opko Health
$3.76 /

-0.125 (-3.22%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
OPK Opko Health
$3.76 /

-0.125 (-3.22%)

07/30/21 Barrington
Opko Health price target lowered to $6 from $8 at Barrington
06/21/21 Ladenburg
Ladenburg starts 'diverse' Opko Health at Buy with $7 price target
06/21/21 Ladenburg
Opko Health initiated with a Buy at Ladenburg
02/19/21 Barrington
Opko Health price target raised to $8 from $7 at Barrington
PFE Pfizer
$43.94 /

-0.25 (-0.57%)

OPK Opko Health
$3.76 /

-0.125 (-3.22%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

OPK Opko Health
$3.76 /

-0.125 (-3.22%)

PFE Pfizer
$43.94 /

-0.25 (-0.57%)

Hot Stocks
CVS Health now offers Pfizer-BioNTech COVID-19 booster shot » 16:01
09/24/21
09/24
16:01
09/24/21
16:01
CVS

CVS Health

$84.88 /

+0.03 (+0.04%)

, PFE

Pfizer

$44.02 /

-0.17 (-0.38%)

, BNTX

BioNTech

$334.40 /

-18.83 (-5.33%)

, MRNA

Moderna

$429.87 /

-24.44 (-5.38%)

, JNJ

Johnson & Johnson

$164.67 /

-0.22 (-0.13%)

CVS Health (CVS)…

CVS Health (CVS) announced that, following approval from the Centers for Disease Control and Prevention, or CDC, based on guidance from the organization's Advisory Committee on Immunization Practices, select CVS Pharmacy and MinuteClinic locations are now offering the Pfizer (PFE)-BioNTech (BNTX) COVID-19 booster shot to eligible populations beginning today. Individuals who initially received the Moderna (MRNA) or Johnson & Johnson (JNJ) COVID-19 vaccine are not eligible for a booster at this time, per guidance from the public health agencies.

ShowHide Related Items >><<
PFE Pfizer
$44.02 /

-0.17 (-0.38%)

MRNA Moderna
$429.87 /

-24.44 (-5.38%)

JNJ Johnson & Johnson
$164.67 /

-0.22 (-0.13%)

CVS CVS Health
$84.88 /

+0.03 (+0.04%)

BNTX BioNTech
$334.40 /

-18.83 (-5.33%)

CVS CVS Health
$84.88 /

+0.03 (+0.04%)

08/31/21 Morgan Stanley
CVS Health price target raised to $114 from $99 at Morgan Stanley
08/20/21 Benchmark
Ontrak price target lowered to $16 from $35 at Benchmark
08/05/21 Deutsche Bank
CVS Health price target raised to $101 from $95 at Deutsche Bank
07/23/21 Tigress Financial
CVS Health shares going to $108 in 12 months, says Tigress Financial
PFE Pfizer
$44.02 /

-0.17 (-0.38%)

09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
BNTX BioNTech
$334.40 /

-18.83 (-5.33%)

08/27/21 UBS
BioNTech price target raised to $300 from $111 at UBS
08/20/21 Canaccord
BioNTech price target raised to $450 from $240 at Canaccord
MRNA Moderna
$429.87 /

-24.44 (-5.38%)

09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
08/12/21 Wells Fargo
Wells says Moderna vaccine looks more effective than Pfizer's against Delta
08/06/21
Fly Intel: Top five analyst downgrades
JNJ Johnson & Johnson
$164.67 /

-0.22 (-0.13%)

09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades J&J to Equal Weight amid limited mid-term newsflow
PFE Pfizer
$44.02 /

-0.17 (-0.38%)

MRNA Moderna
$429.87 /

-24.44 (-5.38%)

JNJ Johnson & Johnson
$164.67 /

-0.22 (-0.13%)

CVS CVS Health
$84.88 /

+0.03 (+0.04%)

BNTX BioNTech
$334.40 /

-18.83 (-5.33%)

PFE Pfizer
$44.02 /

-0.17 (-0.38%)

MRNA Moderna
$429.87 /

-24.44 (-5.38%)

JNJ Johnson & Johnson
$164.67 /

-0.22 (-0.13%)

CVS CVS Health
$84.88 /

+0.03 (+0.04%)

PFE Pfizer
$44.02 /

-0.17 (-0.38%)

MRNA Moderna
$429.87 /

-24.44 (-5.38%)

JNJ Johnson & Johnson
$164.67 /

-0.22 (-0.13%)

CVS CVS Health
$84.88 /

+0.03 (+0.04%)

PFE Pfizer
$44.02 /

-0.17 (-0.38%)

MRNA Moderna
$429.87 /

-24.44 (-5.38%)

JNJ Johnson & Johnson
$164.67 /

-0.22 (-0.13%)

CVS CVS Health
$84.88 /

+0.03 (+0.04%)

Conference/Events
Allogene Therapeutics management to meet virtually with JMP Securities » 15:05
09/24/21
09/24
15:05
09/24/21
15:05
ALLO

Allogene Therapeutics

$25.89 /

-1.745 (-6.31%)

Virtual Meeting to be…

Virtual Meeting to be held on October 1 hosted by JMP Securities.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$25.89 /

-1.745 (-6.31%)

ALLO Allogene Therapeutics
$25.89 /

-1.745 (-6.31%)

09/23/21 Raymond James
Raymond James upgrades Allogene to Outperform after doctor survey
09/23/21 Raymond James
Allogene Therapeutics upgraded to Outperform from Market Perform at Raymond James
08/06/21 B. Riley
Allogene Therapeutics price target lowered to $40 from $52 at B. Riley
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
ALLO Allogene Therapeutics
$25.89 /

-1.745 (-6.31%)

ALLO Allogene Therapeutics
$25.89 /

-1.745 (-6.31%)

Options
AstraZeneca call volume above normal and directionally bullish » 12:45
09/24/21
09/24
12:45
09/24/21
12:45
AZN

AstraZeneca

$60.27 /

+0.77 (+1.29%)

Bullish option flow…

Bullish option flow detected in AstraZeneca with 15,400 calls trading, 3x expected, and implied vol increasing almost 5 points to 26.08%. 10/1 weekly 60 calls and 9/24 weekly 61 calls are the most active options, with total volume in those strikes near 7,000 contracts. The Put/Call Ratio is 0.13. Earnings are expected on November 12th.

ShowHide Related Items >><<
AZN AstraZeneca
$60.27 /

+0.77 (+1.29%)

AZN AstraZeneca
$60.27 /

+0.77 (+1.29%)

09/23/21 Gordon Haskett
Gordon Haskett compares Incyte to Alexion before Astra buyout
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
AZN AstraZeneca
$60.27 /

+0.77 (+1.29%)

AZN AstraZeneca
$60.27 /

+0.77 (+1.29%)

AZN AstraZeneca
$60.27 /

+0.77 (+1.29%)

AZN AstraZeneca
$60.27 /

+0.77 (+1.29%)

Conference/Events
UBS biotechnology analysts to hold an analyst/industry conference call » 09:54
09/24/21
09/24
09:54
09/24/21
09:54
BIIB

Biogen

$289.00 /

-4.19 (-1.43%)

, IONS

Ionis Pharmaceuticals

$37.30 /

+0.07 (+0.19%)

Biotechnology Analysts…

Biotechnology Analysts Bristow and Rajavelu discuss Biogen and Ionis Pharmaceuticals' Tofersen, an antisense oligonucleotide (ASO) therapy being evaluated for the potential treatment of SOD1-associated ALS on an Analyst/Industry conference call to be held on September 24 at 10 am. Webcast Link

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$37.30 /

+0.07 (+0.19%)

BIIB Biogen
$289.00 /

-4.19 (-1.43%)

BIIB Biogen
$289.00 /

-4.19 (-1.43%)

09/24/21 JPMorgan
Eli Lilly remains best positioned growth story in pharma, says JPMorgan
09/23/21 Mizuho
Biogen sales reps banned by D.C. neurology practice, says Mizuho
09/23/21 Cowen
CMS director telling states Aduhelm covered, restrictions can apply, says Cowen
09/22/21 Needham
Biogen initiated with a Buy at Needham
IONS Ionis Pharmaceuticals
$37.30 /

+0.07 (+0.19%)

07/15/21 Canaccord
Bicycle Therapeutics price target raised to $40 from $36 at Canaccord
07/14/21 Benchmark
Bicycle deal 'makes little sense' for Ionis, says Benchmark
07/13/21 William Blair
Bicycle collaboration a positive for Ionis, says William Blair
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
IONS Ionis Pharmaceuticals
$37.30 /

+0.07 (+0.19%)

BIIB Biogen
$289.00 /

-4.19 (-1.43%)

BIIB Biogen
$289.00 /

-4.19 (-1.43%)

IONS Ionis Pharmaceuticals
$37.30 /

+0.07 (+0.19%)

BIIB Biogen
$289.00 /

-4.19 (-1.43%)

BIIB Biogen
$289.00 /

-4.19 (-1.43%)

Hot Stocks
Walgreens: Pfizer Covid-19 vaccine booster shots now available nationwide » 09:54
09/24/21
09/24
09:54
09/24/21
09:54
WBA

Walgreens Boots Alliance

$48.48 /

+0.02 (+0.04%)

, PFE

Pfizer

$44.30 /

+0.11 (+0.25%)

Walgreens (WBA) announced…

Walgreens (WBA) announced that eligible individuals can now receive Pfizer (PFE) COVID-19 booster vaccinations in stores nationwide, following FDA Emergency Use Authorization and new guidance from the Centers for Disease Control and Prevention.

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$48.48 /

+0.02 (+0.04%)

PFE Pfizer
$44.30 /

+0.11 (+0.25%)

WBA Walgreens Boots Alliance
$48.48 /

+0.02 (+0.04%)

07/06/21 Barclays
Walgreens Boots Alliance price target lowered to $53 from $55 at Barclays
07/02/21 Truist
Walgreens Boots Alliance price target lowered to $52 from $58 at Truist
07/02/21 Deutsche Bank
Walgreens Boots Alliance price target lowered to $52 from $55 at Deutsche Bank
07/02/21 Credit Suisse
Walgreens Boots Alliance price target lowered to $48 from $50 at Credit Suisse
PFE Pfizer
$44.30 /

+0.11 (+0.25%)

09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
WBA Walgreens Boots Alliance
$48.48 /

+0.02 (+0.04%)

PFE Pfizer
$44.30 /

+0.11 (+0.25%)

WBA Walgreens Boots Alliance
$48.48 /

+0.02 (+0.04%)

PFE Pfizer
$44.30 /

+0.11 (+0.25%)

WBA Walgreens Boots Alliance
$48.48 /

+0.02 (+0.04%)

PFE Pfizer
$44.30 /

+0.11 (+0.25%)

WBA Walgreens Boots Alliance
$48.48 /

+0.02 (+0.04%)

PFE Pfizer
$44.30 /

+0.11 (+0.25%)

Recommendations
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation » 07:33
09/24/21
09/24
07:33
09/24/21
07:33
PFE

Pfizer

$44.19 /

+0.24 (+0.55%)

, BNTX

BioNTech

$353.21 /

+13.73 (+4.04%)

After the CDC's ACIP…

After the CDC's ACIP committee did not vote in favor of a Pfizer (PFE) booster vaccine recommendation for those aged 18-64 years within an occupational or institutional setting with high risk of COVID, Morgan Stanley analyst Matthew Harrison called the vote "a modest narrowing of the booster recommendation in the near term." However, he notes that the recommendation from the ACIP can change as more data become available, just as the FDA's emergency use authorization on booster recommendation is also subject to change. Harrison has an Equal Weight rating on Pfizer shares.

ShowHide Related Items >><<
PFE Pfizer
$44.19 /

+0.24 (+0.55%)

BNTX BioNTech
$353.21 /

+13.73 (+4.04%)

PFE Pfizer
$44.19 /

+0.24 (+0.55%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
BNTX BioNTech
$353.21 /

+13.73 (+4.04%)

08/27/21 UBS
BioNTech price target raised to $300 from $111 at UBS
08/20/21 Canaccord
BioNTech price target raised to $450 from $240 at Canaccord
08/12/21 Wells Fargo
Wells says Moderna vaccine looks more effective than Pfizer's against Delta
PFE Pfizer
$44.19 /

+0.24 (+0.55%)

BNTX BioNTech
$353.21 /

+13.73 (+4.04%)

PFE Pfizer
$44.19 /

+0.24 (+0.55%)

PFE Pfizer
$44.19 /

+0.24 (+0.55%)

PFE Pfizer
$44.19 /

+0.24 (+0.55%)

Hot Stocks
AstraZeneca, Merck report 'positive' results from PROpel Phase III trial » 06:47
09/24/21
09/24
06:47
09/24/21
06:47
AZN

AstraZeneca

$59.50 /

+0.74 (+1.26%)

, MRK

Merck

$73.05 /

+1.01 (+1.40%)

AstraZeneca (AZN) and…

AstraZeneca (AZN) and Merck (MRK) announced positive high-level results from the PROpel Phase III trial. LYNPARZA in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival versus standard-of-care abiraterone as a 1st-line treatment for men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations. At a planned interim analysis, the Independent Data Monitoring Committee concluded that the trial met the primary endpoint of rPFS in men with mCRPC who had not received treatment in the 1st-line setting including with new hormonal agents or chemotherapy. The trial also showed a trend at this interim analysis towards improved overall survival. However, the data are still immature and the trial will continue to assess OS as a key secondary endpoint. The safety and tolerability were consistent with the known profiles of each medicine.

ShowHide Related Items >><<
MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

09/23/21 Gordon Haskett
Gordon Haskett compares Incyte to Alexion before Astra buyout
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
MRK Merck
$73.05 /

+1.01 (+1.40%)

09/23/21 Citi
Citi opens 'Positive Catalyst Watch' on Merck into Covid data
09/22/21 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
09/21/21 BMO Capital
Regeneron price target raised to $706 from $669 at BMO Capital
09/21/21 Barclays
Merck faces 'compelling series' of catalysts into 2022, says Barclays
MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

Hot Stocks
AstraZeneca's Lynparza meets endpoint in Phase III prostate cancer study » 05:42
09/24/21
09/24
05:42
09/24/21
05:42
AZN

AstraZeneca

$59.50 /

+0.74 (+1.26%)

, MRK

Merck

$73.05 /

+1.01 (+1.40%)

AstraZeneca (AZN) said…

AstraZeneca (AZN) said the PROpel Phase III trial showed it and Merck's (MRK) Lynparza in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival versus standard-of-care abiraterone as a first-line treatment for men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations. At a planned interim analysis, the Independent Data Monitoring Committee concluded that the trial met the primary endpoint of rPFS in men with mCRPC who had not received treatment in the 1st-line setting including with new hormonal agents or chemotherapy. The trial also showed a trend at this interim analysis towards improved overall survival. "However, the data are still immature and the trial will continue to assess OS as a key secondary endpoint. The safety and tolerability were consistent with the known profiles of each medicine," AstraZeneca said in a statement. Reference Link

ShowHide Related Items >><<
MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

09/23/21 Gordon Haskett
Gordon Haskett compares Incyte to Alexion before Astra buyout
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
MRK Merck
$73.05 /

+1.01 (+1.40%)

09/23/21 Citi
Citi opens 'Positive Catalyst Watch' on Merck into Covid data
09/22/21 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
09/21/21 BMO Capital
Regeneron price target raised to $706 from $669 at BMO Capital
09/21/21 Barclays
Merck faces 'compelling series' of catalysts into 2022, says Barclays
MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

MRK Merck
$73.05 /

+1.01 (+1.40%)

AZN AstraZeneca
$59.50 /

+0.74 (+1.26%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.